Vanda Pharmaceuticals (VNDA) Total Current Liabilities (2010 - 2026)

Vanda Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $135.6 million in Q1 2026.

• Quarterly Total Current Liabilities rose 30.46% year-over-year to $135.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.6 million (up 30.46% YoY) and the FY2025 annual result came in at $145.2 million, up 45.19% from the prior year.
• Total Current Liabilities slipped to $135.6 million in Q1 2026 per VNDA's latest filing, from $145.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $145.2 million in Q4 2025 and troughed at $84.8 million in Q3 2023.
• A 5-year average of $101.0 million and a median of $93.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 46.87% in 2022, then declined 8.41% in 2023.
• Over 5 years, Total Current Liabilities stood at $91.4 million in 2022, then dropped by 4.09% to $87.7 million in 2023, then gained by 14.01% to $100.0 million in 2024, then surged by 45.19% to $145.2 million in 2025, then retreated by 6.6% to $135.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $135.6 million, $145.2 million, and $117.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.